Suppliers

CF PharmTech raises additional $50 million

Chinese OINDP developer CF PharmTech announced that it has completed a $50 million Series F financing round approximately six months after completing a $90 million financing round. Investors participating in the latest financing include BioTrack Capital, CICC Qichen, CICC Qide, SAIC Hengxu, GP M&A Fund, and Watson Investment, as well as existing investors Passion Capital and Yuanming Capital.

The company said, “With this new round of funding, CF Pharmtech is more poised than ever to provide respiratory disease treatments for China and global market.”

Prior to this year, CF Pharmtech’s most recent financing round took place in August 2017 when the company said that it had raised $65 million to support development of its own candidates and for expansion of its CDMO services.

Read the CF Pharmtech press release.

published on

July 2, 2020

Featured event:

Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan

September 15-September 18: DDL New Researcher Network Summer Event, London, UK

September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA

September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK

October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA

See all upcoming events

Suppliers